Botox Cosmetic Warning Letter: FDA Frowns On Broad Claims, Wants Correction
Executive Summary
FDA is asking Allergan to correct information in its Botox Cosmetic DTC print campaign regarding the scope of the product's indication
You may also be interested in...
FDA Plays Up Police Role; “White Paper” Recaps Recent Enforcement Steps
An FDA "White Paper" highlighting the agency's recent enforcement actions is part of a concerted effort to draw consumer, industry and media attention to the agency's role in policing industry
FDA Plays Up Police Role; “White Paper” Recaps Recent Enforcement Steps
An FDA "White Paper" highlighting the agency's recent enforcement actions is part of a concerted effort to draw consumer, industry and media attention to the agency's role in policing industry
CDER Ad Division To Create Separate Biologics Review Group
FDA's drug advertising division will establish a separate team to oversee the review of ads for biologics as part of the CBER/CDER consolidation, Division of Drug Marketing, Advertising & Communications Director Tom Abrams said at the Drug Information Association annual meeting in San Antonio June 17